XBITNasdaqPharmaceutical PreparationsFiscal year ends December 31

XBiotech Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$2.00−0.12 (-5.66%)

Close on Oct 19, 2026

Market cap: $60.98M
P/E (TTM): –
Dividend yield: –

XBiotech Inc. cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31
Stock-Based Compensation	3.62	1.75	3.26	5.06	4.46	13	3.36	1.66	1.75	5.57	4.41	7.02	0.74
Deferred Income Taxes	0.01	0	-0.06	-0.82	1.41	-0.05	-0.01	0	–	–	–	–	–
Change in Accounts Receivable	–	–	–	0	4.11	-4.11	0	0	–	–	–	–	–
Change in Accounts Payable	-0.69	-0.36	0.09	0.36	-0.51	-0.33	0.50	-0.08	-2.70	-0.98	0.84	1.07	0.10
Change in Unearned Revenue	–	–	–	–	0	-4.50	4.50	0	–	–	–	–	–
Operating Cash Flow	-40	-31	-19	-15	69	-65	-18	-17	-34	-46	-33	-12	-8.91
Capital Expenditures	-0.29	-1.30	-0.36	-0.59	-3.53	-3.73	-0.20	-0.12	-1.41	-4.75	-2.32	-1.40	-0.06
Sale of Property, Plant & Equipment	–	–	–	–	0	0	675	0	–	–	–	–	–
Investing Cash Flow	-0.29	-1.30	61	-64	-3.53	-3.73	675	-0.12	-1.41	-14	-10	-1.40	-0.06
Dividends Paid	–	–	–	0	-75	0	0	–	–	–	–	–	–
Share Repurchases	–	0	-0.01	0	–	–	–	–	–	–	–	–	–
Stock Issued	–	–	0.00	–	8.00	10	3.80	–	0.70	–	–	–	–
Financing Cash Flow	-10	10	-0.01	0	-67	-410	42	0.20	33	2.94	77	63	12
Foreign Exchange Rate Adjustments	3.33	-5.53	-0.05	-0.96	0.71	1.37	0.15	0.51	-0.83	0.26	-0.05	-0.02	0.00
Net Change in Cash	-47	-27	43	-80	-0.38	-477	699	-16	-2.56	-57	34	50	3.08
Free Cash Flow	-40	-32	-19	-15	66	-69	-18	-17	-35	-51	-36	-13	-8.97
Income Taxes Paid	-0.08	0.09	0.14	–	0	54	0	0	–	–	–	–	–
Interest Paid	0.49	0.40	0	–	–	–	–	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -28.2%

Financial strength

Current ratio: 33.15
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 3266.6%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 0.47
Dividend yield: –